Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, Demonstrated Greater Efficacy with Tirzepatide than Semaglutide in a Preclinical Model ...Middle East

- The combination of ASC47 low dose with tirzepatide in diet-induced obese (DIO) mice resulted in an 87% greater reduction in body weight compared to tirzepatide monotherapy. - ASC47 low dose in combination with tirzepatide demonstrated statistically significantly greater increase in...

Hence then, the article about ascletis announces asc47 a muscle preserving weight loss drug candidate for treatment of obesity demonstrated greater efficacy with tirzepatide than semaglutide in a preclinical model was published today ( Wednesday 13/08/2025 - 02:02 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, Demonstrated Greater Efficacy with Tirzepatide than Semaglutide in a Preclinical Model )

Also on site :

• The Supreme Court Cast Its Lot With Trumpism. It Should Be Very Worried.
• UN renews Sudan ceasefire appeal over ‘unimaginable suffering’ of civilians
• Central African Republic election: Who’s running and what’s at stake?